VVZ-2471 is under clinical development by Vivozon and currently in Phase I for Anxiety Disorders. According to GlobalData, Phase I drugs for Anxiety Disorders have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VVZ-2471’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VVZ-2471 overview

VVZ-2471 is under development for the treatment of opioid addiction, neuropathic pain (neuralgia), anxiety disorders and depression. It is administrated by oral route.

Vivozon overview

Vivozon is a biotechnology company engaged in the research and development of second-generation analgesic drug for treating nervous system, chronic pain, schizophrenia, and depression. It is headquartered in Yongin-si, Gyeonggi-do, South Korea.

For a complete picture of VVZ-2471’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.